A Regulated Digital Health Platform that Accelerates Time to Market and Minimizes Risk

Our BrightInsight Platform is built under a Quality Management System to support and optimize up to Class III regulated drugs, devices, software and Digital Therapeutics through integrated data and actionable insights

A scalable, turnkey solution

Hit the ground running with our managed service model, modular platform architecture and foundational capabilities.

Next-level intelligence

Our integrated data management transforms drug and device data into powerful real-time insights.

Medical-grade security, privacy and compliance

Our advanced quality, security, privacy and compliance processes and tools give you peace of mind.

Learn More

BrightInsight Raises $40M in Series B Funding to Cement its Position as the Leading Global Regulated Digital Health Platform for Biopharma and Medtech

Financing led by Insight Partners, the premier global investor in scaling enterprise software companies, with participation from Series A investors, New Leaf Venture Partners and Eclipse Ventures.

Learn More

BrightInsight and CSL Behring Announce Global Digital Health Partnership to Improve Treatment Experience for Patients with Rare Diseases

CSL Behring selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment.

Learn More

Download our latest white paper to hear from industry experts on how to approach the regulatory strategy for your underlying IoT infrastructure.

If your platform solution does anything beyond transferring, storing, converting the format or displaying medical device data – the definition of a Medical Device Data System (MDDS) – the chances are high that some aspect of a biopharma’s software will be regulated. If you want to manage risk, you need to adopt a more conservative point of view to future-proof your business.

- Bradley Merrill Thompson, Epstein Becker & Green, P.C.

Download